Trials / Completed
CompletedNCT05190146
Epidemiologic Study to Assess the IGRA Positivity in Populations With a High TB Burden
A Multi-country, Epidemiologic Study to Assess the Interferon Gamma Release Assay (IGRA) Positivity, and to Build Capacity to Conduct a Tuberculosis (TB) Vaccine Efficacy Study, in Populations With a High TB Disease Burden
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 7,203 (actual)
- Sponsor
- Gates Medical Research Institute · Academic / Other
- Sex
- All
- Age
- 15 Years – 34 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to conduct a multi-country, multi-site, epidemiologic study designed to assess the proportion of interferon gamma release assay (IGRA) positivity, at site level, and to build capacity to conduct a future TB vaccine efficacy study.
Conditions
Timeline
- Start date
- 2021-12-20
- Primary completion
- 2023-09-11
- Completion
- 2024-08-16
- First posted
- 2022-01-13
- Last updated
- 2024-12-13
Locations
36 sites across 14 countries: Bangladesh, Brazil, Democratic Republic of the Congo, India, Indonesia, Kenya, Mozambique, Peru, Philippines, South Africa, The Gambia, Uganda, Vietnam, Zambia
Source: ClinicalTrials.gov record NCT05190146. Inclusion in this directory is not an endorsement.